Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease

NCT02877134 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

388

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn Disease

Interventions

DRUG: JNJ-64304500
DRUG: Placebo
DRUG: Ustekinumab

Sponsor

Janssen Research & Development, LLC